Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,083 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Maggiolo F, et al. Among authors: castagna a. Antivir Ther. 2021 May;26(3-5):51-57. doi: 10.1177/13596535211042226. Epub 2021 Oct 27. Antivir Ther. 2021. PMID: 35485333 Clinical Trial.
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group. Delaugerre C, et al. Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. doi: 10.1128/AAC.01643-08. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451297 Free PMC article. Clinical Trial.
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.
Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. Morsica G, et al. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592. J Acquir Immune Defic Syndr. 2009. PMID: 19590432
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, Lazzarin A, Clementi M. Canducci F, et al. Among authors: castagna a. J Antimicrob Chemother. 2010 Mar;65(3):425-33. doi: 10.1093/jac/dkp477. Epub 2010 Jan 7. J Antimicrob Chemother. 2010. PMID: 20056687
1,083 results